Preview

April 2019

In the next issue of Pharma Technology Focus, we take look back at a decade of discovery from Action Medical Research, aresearch charity focused on funding breakthrough treatments for conditions affecting children, and round up the biggest drug development success stories from China as a pilot reform puts pressure on pharma companies to invest in innovative research and development projects.


Also, we examine the issue of snake bites and the role of snake venom in drug development, speak to drug policy reform campaigner Amanda Feilding about the most urgent policy issues yet to be addressed in the UK, and investigate the steps big internet companies are taking to stamp out the scourge of dodgy online pharmacies.


Plus, we take a look at the plans for the UK’s first vaccines innovation centre, explore ways that pharma companies are reaching patients in the social media age, and examine how the pharma industry in Italy is developing.

EDITORIAL

Editor | Eloise McLennan

Group Editor | Susanne Hauner

Commissioning Editor | Daniel Garrun

Writers | Chris Lo, Allie Nawrat, Sally Turner​​​​
Magazine Designer | Marzia Del Gaone

Graphic Designers | Paulius Zutautas, Kate Cuntapay, Anett Arc, Sara Basto, Ashley McPherson, Tyrrell Lowe, Noemi Balint
Lead Designer | John Hammond 
Digital Publishing Director | Duncan West

Advertising

Sales Manager | Nimai Amin

+44 (0) 207 936 6453

Marketing

Media Partnership Enquiries | Susanne Hauner

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Pharma Technology Focus is a product of Net Resources International. Copyright 2018 Net Resources International, a trading division of Kable Intelligence Limited. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | The Scottish Uprising Go to article: In this issueGo to article: NSFGo to article: ContentsGo to article: Daiichi JitsugyoGo to article: NewsGo to article: Hapa Company InsightGo to article: BioadviceGo to article: The pharma industry briefingGo to article: Komtur Pharmaceuticals Company InsightGo to article: Komtur PharmaceuticalsGo to article: Where is the UK’s supply of Migraleve?Go to article: AtoZ-CRO GmbH Company InsightGo to article: AtoZ-CRO GmbHGo to article: Drugs from corn? Harvesting Mirexus’ phytoglycogen nano-particleGo to article: Phoenix Group Company InsightGo to article: Phoenix Group Go to article: Castleman disease: does machine learning hold the key to better treatment?Go to article: Capsugel Company InsightGo to article: CalleryGo to article: A health check for Scotland’s pharmaceutical industry Go to article: ImmuMap Company Insight Go to article: ImmuMapGo to article: Moderna’s gamble: what’s behind biotech’s biggest-ever IPO?Go to article: Centaur Clinical | Company InsightGo to article: Centaur ClinicalGo to article: DelSiTech: leveraging silica’s properties to improve drug deliveryGo to article: Alpex Pharma Go to article: AlbypharmaGo to article: ‘Gene genie’: can CRISPR/Cas9 deliver on its promise to transform genome therapy?Go to article: ZenatekGo to article: EventsGo to article: SanofiGo to article: Event: CPhl JapanGo to article: PfanstiehlGo to article: Next issue